HIV Drug Antitrust
SAN FRANCISCO — A federal judge on Thursday dismissed antitrust claims that Gilead Sciences and its cronies blocked a cheap HIV drug from reaching patients, after the AIDS Healthcare Foundation missed the deadline to amend its complaint.